Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.

Cenci T, Martini M, Montano N, D'Alessandris QG, Falchetti ML, Annibali D, Savino M, Bianchi F, Pierconti F, Nasi S, Pallini R, Larocca LM.

Am J Clin Pathol. 2012 Sep;138(3):390-6. doi: 10.1309/AJCPRXHNJQLO09QA.


MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.

Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG.

FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.


Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups.; National Cancer Institute of Canada Clinical Trials Group..

Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.


Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.

Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H.

Cancer. 2010 Jun 15;116(12):3015-24. doi: 10.1002/cncr.25128.


The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.

Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP.

Cell Cycle. 2010 Jul 1;9(13):2663-73.


Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, Delfini R.

Tumori. 2007 May-Jun;93(3):248-56.


[Temozolomide in patients with a glioblastoma multiforme: new developments].

Bromberg JE, Postma TJ.

Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8. Dutch.


[Recent advances in the medical treatment of glioma-temozolomide].

Nishikawa R.

No To Shinkei. 2006 Dec;58(12):1035-41. Japanese. No abstract available.


Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.

Muni R, Minniti G, Lanzetta G, Caporello P, Frati A, Enrici MM, Marchetti P, Enrici RM.

Tumori. 2010 Jan-Feb;96(1):60-4.


BMI1 sustains human glioblastoma multiforme stem cell renewal.

Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G.

J Neurosci. 2009 Jul 15;29(28):8884-96. doi: 10.1523/JNEUROSCI.0968-09.2009.


Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.

Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, Kim ST, Lim DH, Kim WS, Nam DH.

Clin Neurol Neurosurg. 2009 Oct;111(8):679-82. doi: 10.1016/j.clineuro.2009.06.013. Epub 2009 Jul 28.


Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.

Xu F, Yang R, Wu L, He Q, Zhang Z, Zhang Q, Yang Y, Guo J, Chang C, Li X.

Cancer Lett. 2012 Apr 1;317(1):33-40. doi: 10.1016/j.canlet.2011.11.012. Epub 2011 Nov 23.


Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.

Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C.

Strahlenther Onkol. 2011 Nov;187(11):722-8. doi: 10.1007/s00066-011-2230-x. Epub 2011 Oct 28.


Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.

Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, van Tellingen O, van Lohuizen M.

Cancer Cell. 2007 Oct;12(4):328-41.


Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups.; National Cancer Institute of Canada Clinical Trials Group..

N Engl J Med. 2005 Mar 10;352(10):987-96.


Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).

Jalali R.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1622; author reply 1622-3. doi: 10.1016/j.ijrobp.2008.07.054. No abstract available.


BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery.

Facchino S, Abdouh M, Chatoo W, Bernier G.

J Neurosci. 2010 Jul 28;30(30):10096-111. doi: 10.1523/JNEUROSCI.1634-10.2010.


Polycomb group protein Bmi1 expression in colon cancers predicts the survival.

Du J, Li Y, Li J, Zheng J.

Med Oncol. 2010 Dec;27(4):1273-6. doi: 10.1007/s12032-009-9373-y. Epub 2009 Dec 1.


BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer.

Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP, Guo WJ.

Mol Cancer. 2010 Feb 21;9:40. doi: 10.1186/1476-4598-9-40.


Supplemental Content

Support Center